Profiles of serum cytokine levels in Takayasu arteritis patients: Potential utility as biomarkers for monitoring disease activity

Objective.Endoplasmic reticulum aminopeptidase (ERAP)1 is associated with ankylosing spondylitis (AS) and is known to be involved in the clipping of the cytokine receptors interleukin 1 receptor II (IL-1RII), IL-6Rα, and tumor necrosis factor receptor I (TNFRI). We studied the relationship of these serum cytokine receptors and their corresponding cytokines to markers of inflammation and polymorphisms in ERAP1 and ERAP2 in patients with AS.Methods.Sera from patients with AS were assayed for TNF-α, IL-1, IL-6, sTNFRI, sIL-1RII, and sIL-6Rα by ELISA. Genotyping was performed for 3 AS-associated nonsynonymous single-nucleotide polymorphisms in the ERAP1 gene [rs27044(C/G), rs10050860(C/T), and rs30187(C/T)] and 1 in the ERAP2 gene [rs2549782(T/G)]. The serum cytokine and receptor levels were compared between the different genotype groups and correlated to markers of inflammation and disease activity.Results.Eighty patients with AS (21 women) with a mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of 5.3 ± 2.4 were enrolled. There was a significant correlation of sTNFRI with C-reactive protein (CRP; R = 0.43, p < 0.001) and erythrocyte sedimentation rate (ESR; R = 0.30, p = 0.01) but not with BASDAI. Serum cytokine levels were undetectable in the majority of patients. There was no significant difference in serum cytokines or the soluble receptors between patients with the different ERAP1/ERAP2 polymorphisms and their haplotypes. Similarly, there was no relationship of the polymorphisms with the serum cytokine levels nor the cytokine-receptor ratio.Conclusion.Soluble TNFRI levels correlate with ESR and CRP in AS. The ERAP1 and ERAP2 polymorphisms associated with AS do not influence the serum cytokine receptor levels in patients with AS.

Download Full-text

Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis

Journal of Immunology Research ◽

10.1155/2019/3140204 ◽

2019 ◽

Vol 2019 ◽

pp. 1-6 ◽

Cited By ~ 2

Author(s):

Masaki Shimizu ◽

Natsumi Inoue ◽

Mao Mizuta ◽

Yasuo Nakagishi ◽

Akihiro Yachie

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Disease Activity ◽

Influenza A ◽

Systemic Juvenile Idiopathic Arthritis ◽

C Reactive Protein ◽

Serum Cytokine ◽

Tumor Necrosis Factor Receptors ◽

Reactive Protein ◽

Cytokine Levels ◽

Necrosis Factor

To investigate whether serum leucine-rich α2-glycoprotein (LRG) levels are useful as a marker of disease activity in systemic juvenile idiopathic arthritis (s-JIA), we determined serum LRG levels in fifty-nine s-JIA patients, 15 with other subtypes of JIA, 7 with Kawasaki disease (KD), 7 with influenza A infection (flu), 7 with enterohemorrhagic Escherichia coli (EHEC) infection, and 20 healthy controls (HC). Results were compared with the clinical features of s-JIA and serum cytokine levels including interleukin- (IL-) 6, IL-18, and soluble tumor necrosis factor receptors I and II. Serum LRG levels in active s-JIA were higher compared to those in other subtypes of JIA, EHEC, flu patients, and HC. Serum LRG levels were normalized in the inactive s-JIA phase after treatment. Serum LRG levels were positively correlated with serum C-reactive protein and ferritin levels. Serum LRG levels reflected s-JIA disease activity and thus may be useful for monitoring s-JIA disease activity.

Download Full-text

Serum cytokine levels in congenital diaphragmatic hernia: predictive impact for the need for extracorporeal membrane oxygenation?

Klinische Pädiatrie ◽

10.1055/s-0030-1261313 ◽

2010 ◽

Vol 222 (S 01) ◽

Author(s):

M Veit ◽

E Tutdibi ◽

J Tautz ◽

T Schaible ◽

L Gortner

Keyword(s):

Extracorporeal Membrane Oxygenation ◽

Congenital Diaphragmatic Hernia ◽

Diaphragmatic Hernia ◽

Serum Cytokine ◽

Membrane Oxygenation ◽

Cytokine Levels

Download Full-text

An Examination of Generalized Pustular Psoriasis in Pregnancy Based on the Serum Cytokine Levels.

Nishi Nihon Hifuka ◽

10.2336/nishinihonhifu.61.144 ◽

1999 ◽

Vol 61 (2) ◽

pp. 144-147

Author(s):

Miyako KUDO ◽

Yoshihiro UMEBAYASHI ◽

Tomoe KOTSUJI ◽

Fujio OTSUKA

Keyword(s):

Pustular Psoriasis ◽

Serum Cytokine ◽

Cytokine Levels ◽

Generalized Pustular Psoriasis ◽

In Pregnancy

Download Full-text

AB0509 SUSPENSIVE EFFICACY OF TOCILIZUMAB IN TREATMENT-NAÏVE PATIENTS WITH TAKAYASU ARTERITIS: TOCITAKA FRENCH PROSPECTIVE MULTICENTER OPEN-LABELLED TRIAL.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.4592 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1552.3-1552

Author(s):

A. Mekinian ◽

D. Saadoun ◽

J. C. N. F. [email protected] ◽

I. Q. M. F. [email protected] ◽

P. Jégo ◽

...

Keyword(s):

Disease Activity ◽

Takayasu Arteritis ◽

Immunosuppressive Drugs ◽

Relapse Free Survival ◽

Research Support ◽

Free Survival ◽

Treatment Naïve ◽

Steroid Sparing

Objectives:To assess long term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK).Methods:In this multicenter, prospective, open-labelled trial, we aim to evaluate the benefit of adding tocilizumab to steroids in treatment-naïve patients with TAK, on discontinuation of steroids after 6 months of tocilizumab treatment, and to assess relapse-free survival following tocilizumab discontinuation.Results:Thirteen patients with TAK were included, with a median age of 32 years [19-45] and 12 (92%) females. Six (54%) patients met the primary end-point. Among 11 (85%) patients which achieved remission at 6 months, 6 (54%) have reached primary endpoint.. Among the 5 remaining patients which continued steroids, 3 had a prednisone-equivalent dosage < 5mg/day. A significant decrease of disease activity was observed after 6 months of tocilizumab therapy: decrease of median NIH scale (3 [3-4] at baseline, versus 1 [0-2] after 6 months; p <0.001), ITAS-2010 score (5 [2-7] versus 3 [0-8]; p = 0.002), and ITAS-A score (7 [4-10] versus 4 [1-15]; p = 0.0001)]. All patients discontinued tocilizumab after 7 infusions, and no other immunosuppressive drugs was introduced, except for 1 patient which received methotrexate. After 9 and 12 months, respectively 7 (54%) and 6 (50%) patients achieved remission with less than 7.5 mg/day of prednisone, and 9 (69%) and 9 (75%) with doses <10 mg/day. During the 12 months follow-up after tocilizumab discontinuation, a relapse occurred among 5 patients (45%) out of 11 in which achieved remission after 6 months of tocilizumab.No severe AEs were considered related to study treatment and none required tocilizumab interruption or dose reduction. No deaths have occurred during the study period.Conclusion:Tocilizumab seems an effective steroid sparing therapy in TAK but its effect appears to be suspensive.Disclosure of Interests:Arsene Mekinian: None declared, david Saadoun: None declared, [email protected] [email protected]: None declared, [email protected] [email protected]: None declared, Patrick Jégo: None declared, [email protected] [email protected]: None declared, wxv wxv: None declared, Jacques-Eric Gottenberg Grant/research support from: BMS, Pfizer, Consultant of: BMS, Sanofi-Genzyme, UCB, Speakers bureau: Abbvie, Eli Lilly and Co., Roche, Sanofi-Genzyme, UCB, Mathieu Vautier: None declared, [email protected]>; [email protected]>;: None declared, Patrice cacoub: None declared, olivier fain: None declared

Download Full-text

Serum C1q concentration is associated with disease activity in Chinese Takayasu arteritis patients: A case‐control study

Health Science Reports ◽

10.1002/hsr2.252 ◽

2021 ◽

Vol 4 (2) ◽

Author(s):

Si Chen ◽

Haixia Luan ◽

Jianxun He ◽

Yan Wang ◽

Xiaoli Zeng ◽

...

Keyword(s):

Disease Activity ◽

Takayasu Arteritis ◽

Case Control Study ◽

Case Control ◽

Control Study

Download Full-text

Reactive arthritis and undifferentiated peripheral spondyloarthritis share human leucocyte antigen B27 subtypes and serum and synovial fluid cytokine profiles

Rheumatology ◽

10.1093/rheumatology/keaa746 ◽

2020 ◽

Author(s):

Jyoti Ranjan Parida ◽

Sandeep Kumar ◽

Sakir Ahmed ◽

Smriti Chaurasia ◽

Ratnadeep Mukherjee ◽

...

Keyword(s):

Statistical Difference ◽

Human Leucocyte Antigen ◽

Healthy Controls ◽

Hla B27 ◽

Serum Cytokine ◽

Cytokine Profiles ◽

Cytokine Levels ◽

Peripheral Spondyloarthritis ◽

Multiplex Cytokine ◽

Age And Sex

Abstract Objectives Peripheral SpA (pSpA) is comprised of ReA, PsA, enteritis-associated arthritis and undifferentiated pSpA (upSpA). ReA and upSpA share T cell oligotypes and metabolomics in serum and SF. We investigated HLA-B27 subtypes and cytokines in serum and SF that were compared between ReA and upSpA. Methods ReA and upSpA were compared in two cohorts. In cohort I (44 ReA and 56 upSpA), HLA-B27 subtyping was carried out. In cohort II (17 ReA and 21 upSpA), serum and SF cytokines were compared using a multiplex cytokine bead assay (27 cytokines). A total of 28 healthy controls with similar age and sex to cohort II were included for comparison of serum cytokine levels. Results In cohort I, HLA-B27 was positive in 81.8% (36/44) of ReA and 85.71% (48/56) of upSpA patients. HLA-B27 typing was successful in 70 patients (30 ReA and 40 uSpA). HLA-B*2705 was the most common, followed by HLA-B*2704 and HLA-B*2707. Frequencies were the same between ReA and upSpA. In cohort II, 14 cytokines were detectable in the serum of patients. The levels of eight cytokines were higher than in the controls. The cytokine levels of ReA and upSpA were similar. Sixteen cytokines were detectable in the SF of patients. There was no statistical difference in the levels between ReA and upSpA. The cytokine profiles in sera and SF were also similar among HLA-B27-positive and negative patients. Conclusion ReA and upSpA have similar HLA-B27 subtype associations and similar cytokine profiles. They should be considered as a single entity during studies as well as clinical management.

Download Full-text